Influence of sex hormones on melanoma

Journal of Clinical Oncology

Volumn 29, Issue 4, 2011, Pages

  De Giorgi, Vincenzo ^a   Gori, Alessia ^a   Alfaioli, Barbara ^a   Papi, Federica ^a   Grazzini, Marta ^a   Rossari, Susanna ^a   Lotti, Torello ^a   Massi, Daniela ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESSENGER RNA; TAMOXIFEN;

BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; DRUG TREATMENT FAILURE; ESTRADIOL BLOOD LEVEL; GENDER; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MELANOMA; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT;

CELL PROLIFERATION; DISEASE PROGRESSION; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GONADAL STEROID HORMONES; HUMANS; MELANOMA; TREATMENT OUTCOME;

EID: 79952096241     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.1876     Document Type: Letter

References (18)

1. Folkerd EJ, Dowsett M: Influence of sex hormones on cancer progression. J Clin Oncol 28:4038-4044, 2010
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 365:1687-1717, 2005
3. Signoretti S, Loda M: Estrogen receptor beta in prostate cancer: Brake pedal or accelerator? Am J Pathol 159:13-16, 2001
4. Hartman J, Edvardsson K, Lindberg K, et al: Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res 69:6100-6106, 2009
5. Drummond AE, Fuller PJ: The importance of ERbeta signalling in the ovary. J Endocrinol 205:15-23, 2010
6. Ma BB, Oza A, Eisenhauer E, et al: The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers: A study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 14:650-658, 2004 (Pubitemid 39062922)
7. Abe K, Miki Y, Ono K, et al: Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Hum Pathol 41:190-198, 2010
8. Miller JG, Mac Neil S: Gender and cutaneous melanoma. Br J Dermatol 136:657-665, 1997 (Pubitemid 27278070)
9. Cocconi G, Bella M, Calabresi F, et al: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327:516-523, 1992
10. Smith MA, Fine JA, Barnhill RL, et al: Hormonal and reproductive influences and risk of melanoma in women. Int J Epidemiol 27:751-757, 1998 (Pubitemid 28504960)
11. Lea CS, Holly EA, Hartge P, et al: Reproductive risk factors for cutaneous melanoma in women: A case-control study. Am J Epidemiol 165:505-513, 2007 (Pubitemid 46340552)
12. Flowers JL, Seigler HF, McCarty KS Sr, et al: Absence of estrogen receptor in human melanoma as evaluated by a monoclonal antiestrogen receptor antibody. Arch Dermatol 123:764-765, 1987 (Pubitemid 17076169)
13. Hall G, Phillips TJ: Estrogen and skin: The effects of estrogen, menopause, and hormone replacement therapy on the skin. J Am Acad Dermatol 53:555-568, 2005 (Pubitemid 41399920)
14. Stevenson S, Thornton J: Effect of estrogens on skin aging and the potential role of SERMs. Clin Interv Aging 2:283-297, 2007
15. de Giorgi V, Mavilia C, Massi D, et al: Estrogen receptor expression in cutaneous melanoma: A real-time reverse transcriptase-polymerase chain reaction and immunohistochemical study. Arch Dermatol 145:30-36, 2009
16. Schmidt AN, Nanney LB, Boyd AS, et al: Oestrogen receptor-beta expression in melanocytic lesions. Exp Dermatol 15:971-980, 2006 (Pubitemid 44696115)
17. Matsuoka H, Tsubaki M, Yamazoe Y, et al: Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ ERK and PKC/PI3K/Akt pathways. Exp Cell Res 315:2022-2032, 2009
18. Lens MB, Reiman T, Husain AF: Use of tamoxifen in the treatment of malignant melanoma. Cancer 98:1355-1361, 2003